611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

NurseWise 24-Hour Crisis Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Basic InformationLatest News
Scientists Report Progress on Genetic Test for Anal CancerLocation of Body Fat Can Indicate Obesity-Related Cancer RiskBlood Test for Earlier Detection of Pancreatic Cancer FeasibleSocial Contagion Impacts Imaging Use in Breast CancerNew Drug Approved for All Cancers With Genetic MarkerFDA OKs First Cancer Drug by Genetic Type, Not Organ of OriginBlood Test for Pancreatic Cancer Shows Early PromiseEven Small Amounts of Alcohol Can Affect Breast Cancer RiskSuicide Risk Quadruples After Lung Cancer Diagnosis3 Key Lifestyle Factors Can Lower Breast Cancer OddsBlacks More Prone to Colon Cancers That Arise Between Colonoscopies: StudyOne in Five Cancers in the United States Is Considered RareResearchers Say PDE5 Inhibitors Don't Cause MelanomaASCO: Capecitabine May Extend Survival in Biliary Tract CancerOverweight Boys Face Higher Colon Cancer Risk as AdultsYoga, Meditation May Ease Some Breast Cancer SymptomsMore U.S. Women Living With Metastatic Breast CancerASCO: Early Detection of Cancers Up Since Affordable Care ActHPV Vaccine May Also Prevent Cancers Affecting MenChemo Drug May Buy Time for Those With Bile Duct CancerMore U.S. Women Living Longer With Advanced Breast CancerToo Many Americans Still Go Without Cancer ScreeningsNuts! Good Medicine for Colon Cancer Survivors?AUA: E-Cigarettes Can Also Cause DNA Damage to Bladder MucosaE-Cigarettes Linked to Bladder Cancer RiskCould Tai Chi Ease Insomnia in Breast Cancer Survivors?Leukotriene B4 Is Promising Drug Target for Tx of LymphedemaNew VTE Often Occurs During Chemo in Ovarian CancerHope for 1st Drug Against Lymphedema, a Cancer ComplicationPoor Environmental Quality Tied to Higher Cancer RatesTraveling to Academic Hospital May Be Best for Pancreatic CancerNo Routine Screening for Thyroid Cancer: Expert PanelA Movie Instead of Anesthesia for Kids' Radiation TherapyAddressing Your Cancer RiskOsteoporosis Tx Ups Survival in Postmenopausal Breast CancerNot All Hospitals Equal When It Comes to Pancreatic Cancer CareGet Ready for Your 'Capsule Robot' Colon Cancer CheckCervical CA Survivors Often Have Long-Term Fatigue, InsomniaMore Side Effects With CRT Plus Metformin in Head, Neck CancerCervical Cancer May Leave Lasting Imprint on SurvivorsHousehold Income Takes a Hit After Cancer Diagnosis in SpouseLow-Dose Aspirin May Lower Risk for Common Breast Cancer by 20 PercentDrinking Boosts Breast Cancer Risk for Black Women, TooFDA Approves Kinase Inhibitor for Treatment of AMLRydapt Approved for Adults With Acute Myeloid LeukemiaRegorafenib Approved for Hepatocellular CarcinomaStivarga Approved for Liver CancerMoney Pressures Mount When a Spouse Gets CancerGene Expression Profile Improves ID of High-Risk MelanomaFDA Warns Companies Selling Fraudulent Cancer Treatments
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

HPV Vaccine May Also Prevent Cancers Affecting Men

HealthDay News
by -- Robert Preidt
Updated: May 18th 2017

new article illustration

THURSDAY, May 18, 2017 (HealthDay News) -- The same vaccine that cuts the risk of cervical cancer in women might also lower the chances of head and neck cancers in men, new research suggests.

In addition to being linked to cervical cancer, the human papillomavirus (HPV) can cause cancers in the back of the throat, in an area known as the oropharynx. HPV is linked with about 70 percent of these types of cancers in the United States, and the rates of these cancers are rising dramatically, according to the U.S. Centers for Disease Control and Prevention.

The U.S. Food and Drug Administration has approved HPV vaccines for prevention of cervical, vulvar, vaginal and anal cancers in women, and anal cancers in men. However, the HPV vaccine hasn't been FDA-approved for prevention of head and neck cancers, because the vaccines have not been evaluated in clinical trials for that purpose.

"We don't know if there's a potential solution to these rising rates already existing on [drug] shelves," explained study author Dr. Maura Gillison. She is a professor of thoracic/head and neck medical oncology at the University of Texas MD Anderson Cancer Center.

"In the absence of that gold-standard clinical trial, we looked at data from a study that we've been conducting in my lab to address the question as to whether or not existing HPV vaccines could be altering oral HPV infections in the U.S. population," she explained in a Cancer Center news release.

The analysis of data from more than 2,600 Americans, aged 18 to 33, revealed that those who had received HPV vaccination were 88 percent less likely to have oral HPV infections than those who were not vaccinated.

Previous research has shown that HPV-related head and neck cancers are more common in men than women, so Gillison and her colleagues examined whether vaccination was associated with a reduced prevalence of oral HPV infection in men.

"When we compared the prevalence in vaccinated men to non-vaccinated men, we didn't detect any infections in vaccinated men. The data suggests that the vaccine may be reducing the prevalence of those infections by as high as 100 percent," Gillison said.

"We also wanted to determine, accounting for the low rates of vaccination, what proportion of infections could have been prevented," she said.

"We found that just under one million people would have HPV infections in this age group, but, unfortunately, because of low uptake of the vaccine, the burden of infection had only been reduced by 17 percent overall, and only 7 percent in men. We hope the burden of infection will decrease over time with increased vaccination," Gillison said.

The study, conducted while Gillison was at Ohio State University, is to be presented in June at the American Society of Clinical Oncology annual meeting, in Chicago. Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The Oral Cancer Foundation has more on HPV.